Distinguished in Metastatic Brain Tumor

Dr. Maria Werner-Wasik

Radiation Oncology
Jefferson University Physicians
111 S 11th St, 1st Flr Bodine Ctr, 
Philadelphia, PA 
Offers Telehealth
Distinguished in Metastatic Brain Tumor
Jefferson University Physicians
111 S 11th St, 1st Flr Bodine Ctr, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Maria Werner-Wasik is a Radiation Oncologist in Philadelphia, Pennsylvania. Dr. Werner-Wasik is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. Her top areas of expertise are Astrocytoma, Glioblastoma, Schwannoma, and Lung Cancer.

Her clinical research consists of co-authoring 117 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 5 articles in the study of Metastatic Brain Tumor.

Specialties
Radiation Oncology
Licenses
Radiology in PA
Hospital Affiliations
Thomas Jefferson University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO

Locations

JEFFERSON UNIVERSITY PHYSICIANS
111 S 11th St, 1st Flr Bodine Ctr, Philadelphia, PA 19107

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Phase I Trial of High Dose Rate Brachytherapy Combined With Stereotactic Body Radiation Therapy for Intermediate Risk Prostate Cancer Patients
Phase I Trial of High Dose Rate Brachytherapy Combined With Stereotactic Body Radiation Therapy for Intermediate Risk Prostate Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Radiation, Other, Procedure
Study Phase: Phase 1
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Other, Drug, Procedure, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Feasibility Pilot Trial Evaluating Caloric Restriction for Oncology Research in Early Stage Breast Cancer Patients
A Feasibility Pilot Trial Evaluating Caloric Restriction for Oncology Research in Early Stage Breast Cancer Patients
Enrollment Status: Completed
Publish Date: June 06, 2025
Intervention Type: Behavioral, Radiation, Procedure, Other
Study Phase: Not Applicable
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
Enrollment Status: Completed
Publish Date: May 15, 2025
Intervention Type: Radiation, Drug
Study Drug: MK-3475
Study Phase: Phase 1
A Pilot Study to Evaluate the Predictive Value of Circulating Tumor DNA for Clinical Outcome in Patients With Advanced Head and Neck and Lung Cancers
A Pilot Study to Evaluate the Predictive Value of Circulating Tumor DNA for Clinical Outcome in Patients With Advanced Head and Neck and Lung Cancers
Enrollment Status: Completed
Publish Date: May 15, 2025
Intervention Type: Other
A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma
A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma
Enrollment Status: Withdrawn
Publish Date: May 02, 2025
Intervention Type: Drug, Radiation, Biological, Procedure
Study Phase: Phase 1
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug, Biological, Procedure, Radiation
Study Phase: Phase 2
Phase I Study of Alisertib With Concurrent Fractionated Stereotactic Radiation Treatment for Recurrent High Grade Gliomas
Phase I Study of Alisertib With Concurrent Fractionated Stereotactic Radiation Treatment for Recurrent High Grade Gliomas
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug, Radiation, Procedure
Study Phase: Phase 1
A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies
A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Device
Study Phase: Phase 2
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2024
Intervention Type: Other, Drug, Biological, Radiation
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Enrollment Status: Unknown
Publish Date: June 12, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Etoposide, Carboplatin
Study Phase: Phase 3
Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Enrollment Status: Completed
Publish Date: December 21, 2022
Intervention Type: Drug, Radiation, Genetic
Study Phase: Phase 2
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 17, 2022
Intervention Type: Radiation, Drug, Biological, Device, Procedure
Study Drugs: Fludarabine, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Donor Lymphocyte Infusion
Study Phase: Phase 2
View 13 Less Clinical Trials

120 Total Publications

Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase III Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma.
Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase III Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma.
Journal: International journal of radiation oncology, biology, physics
Published: November 01, 2024
Similar Doctors
Distinguished in Metastatic Brain Tumor
Dr. Wenyin J. Shi
Radiation Oncology
Distinguished in Metastatic Brain Tumor
Dr. Wenyin J. Shi
Radiation Oncology

Jefferson University Physicians

111 S 11th St, 
Philadelphia, PA 
 (0.1 miles away)
215-955-6702
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Wenyin Shi is a Radiation Oncologist in Philadelphia, Pennsylvania. Dr. Shi is rated as an Elite provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Astrocytoma, Glioblastoma, Mycosis Fungoides, Brain Tumor, and Gamma Knife Radiosurgery.

Distinguished in Metastatic Brain Tumor
Dr. Stephanie E. Weiss
Radiation Oncology
Distinguished in Metastatic Brain Tumor
Dr. Stephanie E. Weiss
Radiation Oncology

Temple Faculty Practice Plan Inc

3401 N Broad St, 
Philadelphia, PA 
 (3.9 miles away)
215-707-5030
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephanie Weiss is a Radiation Oncologist in Philadelphia, Pennsylvania. Dr. Weiss is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. Her top areas of expertise are Metastatic Brain Tumor, Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), and Breast Cancer.

Distinguished in Metastatic Brain Tumor
Dr. Goldie A. Kurtz
Radiation Oncology
Distinguished in Metastatic Brain Tumor
Dr. Goldie A. Kurtz
Radiation Oncology

Penn Radiation Oncology Perelman - 2nd Floor

3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 
 (1.8 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Goldie Kurtz is a Radiation Oncologist in Philadelphia, Pennsylvania. Dr. Kurtz is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. Her top areas of expertise are Metastatic Brain Tumor, Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), and Meningioma. Dr. Kurtz is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Werner-Wasik's expertise for a condition
ConditionClose
View All 22 Distinguished Conditions
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile